People with multiple sclerosis (MS) who live in rural areas are 17% less likely to receive disease-modifying therapies…
Articles by Marisa Wexler, MS
Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo,…
A new artificial intelligence (AI) tool called MindGlide can accurately calculate, from a single MRI scan, multiple aspects of brain…
The patient support program Cycle Vita, which assists patients throughout the process of medical prescriptions, is now available for…
A small molecule that blocks the activity of a protein called TYK2 in the brain showed promise at reducing disease…
Note: This story was updated April 4, 2025, to clarify the specific disability measures and that tolebrutinib is believed…
Treatment with Tysabri (natalizumab) may help delay disability progression in people with secondary progressive multiple sclerosis (SPMS) over…
Artificial intelligence (AI) platforms did better than most neurologists at answering a 20-question assessment about multiple sclerosis (MS) in…
Antibodies that target proteins from the Epstein-Barr virus (EBV) also can inadvertently attack proteins in the brain, which may…
In the lymph nodes of the neck of people with multiple sclerosis (MS), certain immune cells show abnormalities in…
In people with multiple sclerosis (MS), lesions that get slowly bigger over time, potentially due to chronic inflammation, are…
A statistical model that takes clinical and demographic factors into account could help guide treatment decisions in people with…
Antibodies against a protein found in neurons and in nerve supporting cells, may play a role in driving multiple…
Interactions between the body’s immune system and bacteria that live in the digestive tract — essentially, a person’s gut —…
Using an implantable scaffold to collect immune cells in mice, researchers have gained insights into the immunological mechanisms driving…
Navigating the uncertainty of living with relapsing-remitting multiple sclerosis (RRMS) brings a number of challenges, a study shows. That…
Children with multiple sclerosis (MS) who were exposed to sunlight for at least half an hour per day during…
Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with multiple…
The rate of relapses in children with pediatric-onset multiple sclerosis (POMS) tends to increase around the time that menstruation…
Smoking and obesity are both independently associated with faster disease progression in multiple sclerosis (MS), but when both risk…
A Phase 2 clinical trial is currently recruiting adults with relapsing types of multiple sclerosis (MS) to investigate…
Less frequent Ocrevus (ocrelizumab) infusions are as effective as standard dosing — when treatment is given typically every six…
Stem cell transplant can be considered a viable treatment option for people with relapsing-remitting multiple sclerosis (MS) who are…
The U.S. Food and Drug Administration (FDA) has added a new boxed warning to the prescribing information for glatiramer acetate,…
TG Therapeutics is working to develop a subcutaneous, or under-the-skin, version of Briumvi (ublituximab-xiiy), its approved therapy…
Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people…
For women with multiple sclerosis (MS), disability starts to worsen significantly faster after menopause, according to a new study.
OCS-05, an experimental medication that Oculis is developing to treat acute optic neuritis, a common symptom of multiple…
IRX4204, a compound that Io Therapeutics is developing to treat neurological diseases, facilitated myelin repair and improved walking…
Treatment with Tecfidera (dimethyl fumarate) significantly reduces relapse rates for people with multiple sclerosis (MS), and most MS…